Biovian, a pharmaceutical company, and 3P Biopharmaceuticals, a biotechnology company, agreed to form 3PBIOVIAN. Financial terms were not disclosed. "We are thrilled about this opportunity and the new chapter for our combined companies. The highly synergistic and comprehensive service offering allows 3PBIOVIAN to further enhance its competitiveness in the biologics CDMO market. With a combined 40-year track record and a commitment to quality, both companies have always prioritized customer-centric service. The consolidation of these two technically and financially strong players creates a powerful global end-to-end service provider. We are also extremely glad to be able to continue the journey alongside Keensight, jointly investing in the future development of the firm, and striving to further improve our client satisfaction as well as build a great workplace for our highly talented people,” Antti Nieminen, Biovian CEO.